MedTrace Logo

AZD5672 Absolute Bioavailability Study

NCT00746837 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2010-12-02

No results posted yet for this study

Summary

The purpose of the study is to estimate the absolute bioavailability at steady state of 2 doses of AZD5672 (50 mg and 150 mg administered orally once daily)

Conditions

  • Healthy Volunteers

Interventions

DRUG

AZD5672

single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period

DRUG

AZD5672

50 mg od, 12 days

DRUG

AZD5672

150mg od, 12 days

Sponsors & Collaborators

Principal Investigators

  • Mark Layton, MD, PhD · AstraZeneca R&D, Charnwood, UK

  • Tania Hugo · PAREXEL Clinical Pharmacology Research Unit

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00746837 on ClinicalTrials.gov